Digene strengthens diagnostic patents:
This article was originally published in Clinica
Executive Summary
US diagnostics company Digene has received a European patent for its Hybrid Capture technology. All of the company's tests are based on this technology, which uses signal amplification to detect as few as 100 molecules of DNA or RNA in a rapid format. The patent strengthens the company's protection for its human papillomavirus products and core technology, according to Beltsville, Maryland-based Digene.
You may also be interested in...
IPO Year In Review: Record-Year Bodes Well For 2021, And For More SPACs
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott Capitalizes On Pandemic Testing Boom; Device Sales Stay Almost Flat
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
Agios’ Mitapivat Shows Improvement In Regularly Transfused PKD Patients
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: